1. An apparatus comprising:
a first squelch circuit configured to detect possible squelch signals in a communication signal; and
a second squelch circuit configured to
i) operate in a low-power state responsive to the first squelch circuit detecting none of the possible squelch signals in the communication signal, and
ii) operate in a high-power state responsive to the first squelch circuit detecting one of the possible squelch signals in the communication signal.
2. The apparatus of claim I, wherein the second squelch circuit is further configured to:
iii) determine an out-of-band (OOB) signaling sequence based on a squelch signal in the communication signal responsive to operating in the high-power state.
3. The apparatus of claim 2, wherein the first squelch circuit comprises:
a first squelch detector configured to detect one of the possible squelch signals in the communication signal responsive to an amplitude of the one of the possible squelch signals being greater than a threshold amplitude.
4. The apparatus of claim 3, wherein the first squelch circuit further comprises:
a signal detector configured to negate a control signal responsive to the first squelch detector detecting one of the possible squelch signals in the communication signal;
wherein the second squelch circuit is further configured to operate in the high-power state responsive to the control signal being negated.
5. The apparatus of claim 3, wherein the first squelch circuit further comprises:
a signal detector configured to negate a first control signal responsive to the first squelch detector detecting one of the possible squelch signals in the communication signal; and
logic configured to negate a second control signal responsive to
i) the first control signal being negated, and
ii) an enable signal being asserted;
wherein the second squelch circuit is further configured to operate in the high-power state responsive to the second control signal being negated.
6. The apparatus of claim 5, wherein:
the enable signal represents a link status of a link, wherein the link provides the communication signal to the apparatus.
7. The apparatus of claim 2, wherein the second squelch circuit comprises:
a second squelch detector configured to detect the squelch signal in the communication signal responsive to
i) the first squelch detector detecting one of the possible squelch signals in the communication signal,
ii) an amplitude of the squelch signal being greater than a first threshold amplitude, and
iii) the amplitude of the squelch signal being less than a second threshold amplitude, wherein the second threshold amplitude is greater than the first threshold amplitude.
8. The apparatus of claim 7, wherein the second squelch circuit further comprises:
an OOB signal detector configured to determine the OOB signaling sequence based on the squelch signal responsive to the second squelch detector detecting the squelch signal in the communication signal.
9. The apparatus of claim 1, wherein the communication signal is selected from the group consisting of
a serial ATA (SATA) signal;
a PCI Express (PCIe) signal; and
a Universal Serial Bus (USB) signal.
10. One or more integrated circuits comprising the apparatus of claim 1.
11. An analog front end comprising the apparatus of claim 1.
12. A communications device comprising the analog front end of claim 11.
13. The apparatus of claim 1, wherein the apparatus is compliant with all or part of the Serial ATA International Organization: Serial ATA Revision 3.0 specification.
14. A method comprising:
detecting possible squelch signals in a communication signal in a first squelch circuit;
operating a second squelch circuit in a low-power state responsive to detecting none of the possible squelch signals in the communication signal in the first squelch circuit; and
operating the second squelch circuit in a high-power state responsive to detecting one of the possible squelch signals in the communication signal in the first squelch circuit.
15. The method of claim 14, further comprising:
determining an out-of-band (OOB) signaling sequence based on one of the possible squelch signals responsive to operating in the high-power state.
16. The method of claim 15, further comprising:
detecting one of the possible squelch signals in the communication signal responsive to an amplitude of the one of the possible squelch signals being greater than a threshold amplitude.
17. The method of claim 16, further comprising:
negating a control signal responsive to detecting one of the possible squelch signals in the communication signal; and
operating the second squelch circuit in the high-power state responsive to the control signal being negated.
18. The method of claim 16, further comprising:
negating a first control signal responsive to the first squelch detector detecting one of the possible squelch signals in the communication signal;
negating a second control signal responsive to
i) the first control signal being negated, and
ii) an enable signal being asserted; and
operating the second squelch circuit in the high-power state responsive to the second control signal being negated.
19. The method of claim 18, wherein:
the enable signal represents a link status of a link, wherein the link provides the communication signal.
20. The method of claim 15, further comprising:
detecting a squelch signal in the communication signal responsive to
i) detecting one of the possible squelch signals in the communication signal,
ii) an amplitude of the squelch signal being greater than a first threshold amplitude, and
iii) the amplitude of the squelch signal being less than a second threshold amplitude, wherein the second threshold amplitude is greater than the first threshold amplitude.
21. The method of claim 20, further comprising:
determining the OOB signaling sequence based on the squelch signal responsive to detecting the squelch signal in the communication signal.
22. The method of claim 14, wherein the communication signal is selected from the group consisting of:
a serial ATA (SATA) signal;
a PCI Express (PCIe) signal; and
a Universal Serial Bus (USB) signal.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method of preparing an isolated myeloid derived suppressor cell (MDSC) comprising:
a) contacting an embryonic stem (ES) cell with an effective amount of kit ligand (KL) (stem cell factor), vascular endothelial growth factor (VEGF), FMS-like tyrosine kinase 3 (Flt3L), thrombopoietin (TPO), and macrophage colony-stimulating factor (M-CSF); and
b) culturing said ES cell under conditions suitable for propagation of said cell, thereby obtaining a preparation of an isolated MDSC.
2. The method of claim 1, further comprising cryopreservation of said MDSC.
3. The method of claim 1, wherein the ES cell is a mammalian ES cell.
4. The method of claim 3, wherein the ES cell is a human ES cell.
5. The method of claim 1, wherein the isolated MDSC expresses at least one of the cell surface markers selected from the group consisting of CD33, CD115, F480, Ly-6C, CD11b, Gr-1, and IL-4R.
6. An isolated MDSC obtained by the method according to claim 1.
7. A method of preparing an isolated myeloid derived suppressor cell (MDSC) comprising:
a) contacting a hematopoietic stem cell (HSC) with an effective amount of kit ligand (KL) (stem cell factor), vascular endothelial growth factor (VEGF), FMS-like tyrosine kinase 3 (Flt3L), thrombopoietin (TPO), and macrophage colony-stimulating factor (M-CSF); and
b) culturing said HSC under conditions suitable for propagation of said cell, thereby obtaining a preparation of an isolated MDSC.
8. The method of claim 7, further comprising cryopreservation of said MDSC.
9. The method of claim 7, wherein the HSC is a mammalian HSC.
10. The method of claim 9, wherein the HSC is a human HSC.
11. The method of claim 7, wherein the isolated MDSC expresses at least one of the cell surface markers selected from the group consisting CD33, CD115, F480, Ly-6C, CD11b, Gr-1, and IL-4R.
12. An isolated MDSC obtained by the method according to claim 7.
13. A method of treating a disorder amenable to cell-based treatment in a mammal, comprising administering a pharmaceutically effective amount of the isolated MDSC of claim 6 to a mammal in need thereof.
14. The method of claim 13, wherein the disorder is selected from the group consisting of graft-versus-host disease (GVHD) and an autoimmune disorder.
15. The method of claim 3, wherein the isolated MDSC expresses at least one of the cell surface markers selected from the group consisting of CD115, F480, Ly-6C, CD11b, Gr-1, VEGF receptor, CD40 and IL-4R.
16. The method of claim 4, wherein the isolated MDSC expresses at least one of the cell surface markers selected from the group consisting of CD11b, CD33, CD15, and CD16.
17. The method of claim 4, wherein the isolated MDSC expresses CD11b and CD33.
18. The method of claim 3, wherein the isolated MDSC expresses CD11b and Gr-1.
19. The method of claim 17, wherein the isolated MDSC further expresses CD15 or CD16.
20. The method of claim 17, wherein the isolated MDSC further expresses CD15 and CD16.
21. A method of treating a disorder amenable to cell-based treatment in a mammal, comprising administering a pharmaceutically effective amount of the isolated MDSC of claim 12 to a mammal in need thereof.
22. The method of claim 21, wherein the disorder is selected from the group consisting of graft-versus-host disease (GVHD) and an autoimmune disorder.
23. The method of claim 9, wherein the isolated MDSC expresses at least one of the cell surface markers selected from the group consisting of CD115, F480, Ly-6C, CD11b, Gr-1, VEGF receptor, CD40 and IL-4R.
24. The method of claim 10, wherein the isolated MDSC expresses at least one of the cell surface markers selected from the group consisting of CD11b, CD33, CD15, and CD16.
25. The method of claim 10, wherein the isolated MDSC expresses CD11b and CD33.
26. The method of claim 9, wherein the isolated MDSC expresses CD11b and Gr-1.
27. The method of claim 25, wherein the isolated MDSC further expresses CD15 or CD16.
28. The method of claim 25, wherein the isolated MDSC further expresses CD15 and CD16.